<DOC>
	<DOCNO>NCT01925183</DOCNO>
	<brief_summary>Response-guided triple-therapy boceprevir ( BOC ) combination pegylated interferon ( PEGIFN ) ribavirin ( RBV ) current standard care HIV-negative patient infect hepatitis C genotype ( HCV-GT ) 1 . In contrast , HIV-positive patient , fix treatment duration 48 week use . The aim study assess efficacy safety response-guided triple-therapy BOC combination PEGIFN RBV HIV-positive patient . Thus , treatment duration individualize base HCV-RNA negativity treatment week 8 ( W8 ) . All patient receive 4 week PEGIFN/RBV lead-in . Patients undetectable HCV-RNA W8 treat 24 week BOC/PEGIFN/RBV triple-therapy result total treatment duration 28 week , patient detectable HCV-RNA W8 receive 44 week BOC/PEGIFN/RBV triple-therapy total treatment duration 48 week .</brief_summary>
	<brief_title>Individualized Triple-therapy Using Boceprevir HIV-positive Patients With Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Confirmed HIV infection ( antiHIV1/2 antibody positive ) . Chronic HCV infection ( antiHCV positive , HCVRNA detectable &gt; 6 month ) . HCVGT 1 infection . Age ≥18 year ≤65 year . No prior treatment BOC/PEGIFN/RBV . CD4+ cell count &gt; 200 cells/µL . Stable antiretroviral therapy ( ART ) include tenofovir/emtricitabine ( Truvada® , Gilead ) raltegravir ( Isentress® , MSD ) HIVRNA &lt; 50 copies/mL . Valid result transient elastography liver biopsy within 6 month prior enrollment . Female patient childbearing potential must agree use effective contraceptive treatment 4 month treatment conclude . Male patient female partner must agree use effective contraceptive treatment 7 month treatment conclude . HCVGT HCVGT 1 . Cirrhotic patient ( define METAVIR F4 liver biopsy liver stiffness &gt; 12.3 kPa ) decompensated liver disease ( ChildPugh stage B/C ) . Chronic liver disease hepatitis C virus infection ( hepatitis B virus infection : HBsAg positivity , nonalcoholic steatohepatitis , autoimmune hepatitis , primary biliary cirrhosis , hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency , cystic fibrosis ) . Significant cardiac disease ( ejection fraction &lt; 40 % echocardiography ) . Significant pulmonary disease ( COPD stage GOLD III/IV ) . Significant renal disease ( serum creatinine &gt; 1.5 mg/dL ) . Subjects take medication ( ) is/are highly dependent CYP3A4/5 clearance , elevate plasma concentration associate serious and/or lifethreatening event limited , orally administer midazolam , pimozide , amiodarone , flecainide , propafenone , quinidine , ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) . Contraindications boceprevir ( Victrelis® , MSD ) , pegylated interferon alpha2a ( Pegasys® , Roche ) ribavirin ( Copegus® , Roche ) , list section 4.3 respective summary product characteristic ( SmPCs ) . Ongoing alcohol abuse ( average daily alcohol consumption &gt; 50g ) . Ongoing illicit drug abuse . Unwillingness give write informed consent . Pregnancy breastfeed . Women wish become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Boceprevir</keyword>
	<keyword>HIV/HCV-coinfection</keyword>
	<keyword>HIV/HCV coinfection</keyword>
	<keyword>HIV/HCV</keyword>
	<keyword>Response-guided therapy</keyword>
</DOC>